<?xml version="1.0" encoding="UTF-8"?>
<p id="Par90">The described minimum clinically relevant difference is reasonable given what has been observed in other trials; e.g. an upgrade in complete responses (CRs) of 26% was observed by Roussel and colleagues where high-dose melphalan was augmented by IV bortezomib in a phase II study in the front-line setting (comparing the impact with that of matched historical controls receiving high-dose melphalan alone) [
 <xref ref-type="bibr" rid="CR19">19</xref>]. Therefore, the estimation of a 20% increase in ≥ VGPR rate seems reasonable to hypothesise.
</p>
